A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Clinical trial NCT01566721 · COMPLETED

Trial details

NCT number: NCT01566721
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2012-05-17
Primary completion: 2015-03-10
Enrollment: 2577

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.